Early phase cancer trials: how to draft a successful blueprint
Early phase cancer drug trials need specialised sites and staff, especially since these studies target specific patients.
By
Oncology
Latest in
Oncology
Treadwell begins subject dosing in Phase Ib/II cancer therapy trial
The trial will analyse the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of CFI-402257.
Pipeline Moves: Merck KGaA’s berzosertib progression shot in small-cell lung cancer reviewed after Phase II discontinued
We also review berzosertib in solid tumours, as well as other assets in myelodysplastic syndrome, cervical cancer, and Dengue fever.
By
Daiichi Sankyo Phase III quizartinib trial reports positive AML data
Treatment with quizartinib plus chemotherapy offered a 22.4% decline in mortality risk versus standard chemotherapy alone.
AbbVie reports data from Phase II large B-cell lymphoma therapy trial
The trial subjects had an overall response rate and complete response rate of 63% and 39%, respectively.
ASCO rectal cancer trial result draw publicity but what is the impact?
Data from a Phase II rectal cancer trial was in the limelight at this year’s ASCO meeting but the bigger…
By
NRG selects Pieces to expedite subject identification for cancer trial
The trial is expected to enroll 9,500 subjects, which requires identifying enough number of eligible participants from US sites.
How oncology clinical trials can use data to dig deeper on diversity
This year’s ASCO meeting highlighted the need to boost diversity in cancer studies. Experts tell Clinical Trials Arena how data…
By